Você procurou por: randomized double blind study (Inglês - Maltês)

double blind
double blind

is randomised, double-blind, multinational study.
to trasfużjonijiet ta 'ċelluli ħomor tad- demm f' pazjenti li kienu qed jirċievu l- kimoterapija ġew assessjati fi studju randomized, double- blind, multi- nazzjonali.

each double-blind study period lasted 2 weeks.
kull perjodu mill-istudju double-blind ħa ġimagħtejn.

a randomized double-blind placebo controlled study was conducted in 83 patients with fap.
sar studju b’mod każwali fejn la t-tabib u lanqas il-pazjent ma kienu jafu x’qed jingħata, ikkontrollat bil-plaċebo fi 83 pazjent bl-fap.

study 4 was a randomized, double-blind clinical study assessing ulipristal acetate 5 or 10 mg.
studju 4 kien studju kliniku, double-blind, randomizzat li jivvaluta ulipristal acetate 5 jew 10 mg.

double-blind placebo-controlled studies
studji double-blind ikkontrollati bi plaċebo

study 1 was double-blind placebo controlled.
l-istudju 1 kien double blind kkontrollat bi plaċebo.

study 02507 was a randomized, double-blind, placebo-controlled, multicenter clinical study in 40 patients with gd1.
l-istudju 02507 kien studju kliniku multiċentriku, magħmul b’mod arbitrarju, bi blindaġġ doppju, ikkontrollat bi plaċebo, fuq 40 pazjent b’gd1.

in the double blind study sp512 part i, 177 patients received rotigotine and 96 patients received placebo.
fl-istudju double blind sp512 part i, 177 pazjent rċivew rotigotine u 96 pazjent irċivew il-plaċebo.

the febuxostat allopurinol controlled trial (fact) study was a phase 3, randomized, double-blind, multicenter, 52-week study.
l- istudju prova ta ’ febuxostat ikkontrollat b’ allopurinol (fact) kien studju ta ’ 52 ġimgħa, ta ’ fażi 3, randomised, double- blind u multicenter.

the double–blind study population comprised 832 male patients of whom 551 patients received xiapex and 281 received placebo.
il-popolazzjoni tal-istudju double-blind kienet tinkludi 832 pazjenti rġiel li minnhom 551 pazjent irċivew xiapex u 281 irċivew plaċebo.

two randomized, parallel group, double-blind studies were performed in patients previously treated with anticagulation therapy.
Żewġ studji double-blind li fihom il-parteċipanti ntgħażlu b’mod każwali, ta’ grupp parallel, twettqu f’pazjenti li kienu kkurati fil-passat b’terapija kontra l-koagulazzjoni.

in a second double-blind study, 213 patients received rotigotine, 227 received ropinirole and 117 patients received placebo.
fit- tieni studju double- blind, 213 pazjent irċivew rotigotine, 227 irċivew ropinirole u 117 pazjenti rċivew il- plaċebo.

the mah shall provide the 1 year data report on a randomized, double-blind placebo- controlled large safety study, based on a protocol agreed with chmp.
id-detentur tal-awtorizzazzjoni għat-tqegħid fis-suq (mah) għandu jipprovdi r-rapport minn dejta ta’ sena dwar studju kbir ta’ sigurtà, randomised double-blind u kkontrollat bi plaċebo, ibbażat fuq protokoll miftiehem mas-chmp.

a small (n=83), phase ii, randomised, double-blind study in patients receiving chemotherapy for od
grupp ta 'pegfilgrastim meta mqabbla mal- grupp tal- plaċebo (1% versus 14%, p < 0. 001; u 2% versus od

a total of 234 subjects aged 1 to 17 years were treated in a randomized, double-blind, multi-centre, placebo controlled parallel group, dose ranging study.
total ta’ 234 suġġett ta’ età ta’ bejn sena u 17-il sena kienu trattati fi studju b’mod każwali, double- blind, multi-ċentriku, ikkontrollat fl-istess ħin bi grupp li ngħata l-plaċebo, u dożi varji.

the safety and efficacy of soliris in pnh patients with haemolysis were assessed in a randomized, double-blind, placebo-controlled 26 week study (c04-001).
is-sigurtà u l-effikaċja ta’ soliris f’pazjenti pnh b’emodijalisi kienu evalwati fi studju double-blind, ikkontrollat bil-plaċebo, magħmul b’għażla każwali, fuq 26 ġimgħa (c04-001).

a randomized, double-blind study was conducted to assess the safety and efficacy of abatacept or infliximab versus placebo in patients with an inadequate response to methotrexate (study v).
sar studju fuq bażi każwali, double blind biex jivvaluta s-sigurtà u l-effikaċja ta’ abatacept jew infliximab kontra l-plaċebo f’pazjenti li ma kellhomx rispons adegwat għal methotrexate (studju v).

results at 48 weeks of randomised, double blind studies comparing entecavir (etv) to lamivudine
ir- riżultati wara 48 ġimgħa ta ’ studji magħmulin b’ mod każwali, double blind li jqabblu entecavir (etv) ma ’ lamivudine (lvd) f’ pazjenti pożittivi għal hbeag (022) u f’ pazjenti negattivi għal hbeag (027) jidhru fit- tabella.

a pivotal phase 3, multi-centre, international, randomized, double-blind placebo-controlled study of single-agent sunitinib was conducted in patients with unresectable pnet.
sar studju pivitali internazzjonali, multiċentri, randomizzat, double-blind, ikkontrollat bi plaċebo, ta’ fażi 3, tas-sustanz unika sunitinib f’pazjenti li kellhom pnet li ma setax jitneħħa.